Intervention Review

You have free access to this content

Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia

  1. Alessandro Squizzato1,*,
  2. Erica Romualdi2,
  3. Francesco Passamonti3,
  4. Saskia Middeldorp4

Editorial Group: Cochrane Haematological Malignancies Group

Published Online: 30 APR 2013

Assessed as up-to-date: 31 OCT 2012

DOI: 10.1002/14651858.CD006503.pub3


How to Cite

Squizzato A, Romualdi E, Passamonti F, Middeldorp S. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia. Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD006503. DOI: 10.1002/14651858.CD006503.pub3.

Author Information

  1. 1

    University of Insubria, Research Center on Thromboembolic Disorders and Antithrombotic Therapies, Department of Clinical and Experimental Medicine, School of Medicine, Varese, Italy

  2. 2

    University of Insubria, Department of Clinical Medicine, Varese, Italy

  3. 3

    Ospedale di Circolo e Fondazione Macchi, Division of Hematology, Department of Internal Medicine, Varese, Italy

  4. 4

    Academic Medical Center, Department of Vascular Medicine, Amsterdam, Netherlands

*Alessandro Squizzato, Research Center on Thromboembolic Disorders and Antithrombotic Therapies, Department of Clinical and Experimental Medicine, School of Medicine, University of Insubria, c/o Medicina 1, Ospedale di Circolo, viale Borri, 57, Varese, 21100, Italy. alexsquizzo@libero.it. alessandro.squizzato@uninsubria.it.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 30 APR 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
  5. References to other published versions of this review
ECLAP 2004 {published data only}
GISP 1997 {published data only}

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
  5. References to other published versions of this review
Finelli 1991 {published data only}
  • Finelli C, Palareti G, Poggi M, Torricelli P, Vianelli N, Fiacchini M, et al. Ticlopidine lowers plasma fibrinogen in patients with polycythaemia rubra vera and additional thrombotic risk factors. Acta Haematologica 1991;85:113-8.
Tartaglia 1986 {published data only}
  • Tartaglia AP, Goldberg JD, Berck PD, Wasserman LR. Adverse effects of antiaggregant platelet therapy in the treatment of polycythaemia vera. Seminars in Hematology 1986;23:172-6.

References to ongoing studies

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
  5. References to other published versions of this review
ISCLAP {published data only}
  • Clopidogrel and Aspirin for the Treatment of Polycythemia Vera (ISCLAP). NCT00940784. http://clinicaltrials.gov last search: 26 February 2012.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
  5. References to other published versions of this review
ACCP 2012
  • Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;2 Suppl:e89S-e119S.
Alvarez-Larran 2010
  • Alvarez-Larran A, Cervantes F, Pereira A, Arellano-Rodrigo E, Perez-Andreu V, Hernandez-Boluda JC, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 2010;116:1205-10.
Ania 1994
ATC 2002
  • Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. British Medical Journal 2002;324:71-86.
Campbell 2005
  • Campbell PJ, Green AR. Management of polycythaemia vera and essential thrombocythaemia. Hematology/Education Program of the American Society of Hematology 2005;1:201-8.
Cortelazzo 1990
  • Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythaemia. Journal of Clinical Oncology 1990;8:556-62.
Cortelazzo 1995
  • Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, et al. Hydroxyurea for patients with essential thrombocythaemia and high risk of thrombosis. New England Journal of Medicine 1995;332:1132-6.
Deeks 2011
  • Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
Egger 1997
Finazzi 2005
  • Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, et al. Acute leukaemia in polycythaemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005;105:2664-70.
GISP 1995
Harrison 2005
  • Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. New England Journal of Medicine 2005;353(1):33-45.
Higgins 2003
Higgins 2011a
  • Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
Higgins 2011b
  • Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 www.cochrane-handbook.org.
Landolfi 1992
  • Landolfi R, Ciabattoni G, Pugliese F, et al. Increased thromboxane biosynthesis in patients with polycythaemia vera: evidence for aspirin-suppressible platelet activation in vivo. Blood 1992;80:1965-71.
Landolfi 1997
Lau 2006
Maclure 1987
Marchioli 2005
  • Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythaemia vera. Journal of Clinical Oncology 2005;23:2224-32.
Mesa 1999
Pardanani 2011
Parmar 1998
Passamonti 2004
  • Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythaemia vera and essential thrombocythaemia. American Journal of Medicine 2004;117:755-61.
PRISMA
RevMan 5 [Computer program]
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagan: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Rocca 1995
Sterne 2011
  • Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011].. The Cochrane Collaboration, 2011 www.cochrane-handbook.org.
WHO 2002

References to other published versions of this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
  5. References to other published versions of this review
Squizzato 2008a
  • Squizzato A, Romualdi E, Middeldorp S. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2008, issue 2. [DOI: 10.1002/14651858.CD006503.pub2; CD006503]